Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Marschner

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
The Medical Journal of Australia|June 18, 2002
Specifying objectives and outcomes for clinical trialsVal Gebski, Ian Marschner, Anthony C Keech
Pharmaceutical Statistics|October 2, 2020
Recurrent time-to-event models with ordinal outcomesVal Gebski, Karen Byth, Rebecca Asher, et al.
Pharmaceutical Statistics|March 18, 2021
Using recurrent time-to-event models with multinomial outcomes to generate toxicity profilesVal Gebski, Ian Marschner, Rebecca Asher, et al.
The Medical Journal of Australia|June 23, 2025
Platform trials: key features, when to use them and methodological challengesRobert Mahar, Steve Webb, Ian Marschner, et al.
Seminars in Perinatology|July 8, 2023
To guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomesWilliam Odita Tarnow-Mordi, Kristy Robledo, Ian Marschner, et al.
British Journal of Anaesthesia|March 17, 2023
Importance of sequential methods in meta-analysis: implications for postoperative mortality, delirium, and stroke managementThomas Payne, Ben Moran, John Loadsman, et al.
Clinical Trials (London, England)|November 26, 2008
Parametric conditional frailty models for recurrent cardiovascular events in the lipid studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
JCO Precision Oncology|July 23, 2021
Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisPeey-Sei Kok, Won-Hee Yoon, Sally Lord, et al.
JAMA Oncology|February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysisGeorgia Ritchie, Harry Gasper, Johnathan Man, et al.
Acta Oncologica (Stockholm, Sweden)|October 15, 2019
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of biasKelli Snyders, Doah Cho, Jun Hee Hong, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
The Medical Journal of Australia|June 18, 2002
Specifying objectives and outcomes for clinical trialsVal Gebski, Ian Marschner, Anthony C Keech
Pharmaceutical Statistics|October 2, 2020
Recurrent time-to-event models with ordinal outcomesVal Gebski, Karen Byth, Rebecca Asher, et al.
Pharmaceutical Statistics|March 18, 2021
Using recurrent time-to-event models with multinomial outcomes to generate toxicity profilesVal Gebski, Ian Marschner, Rebecca Asher, et al.
The Medical Journal of Australia|June 23, 2025
Platform trials: key features, when to use them and methodological challengesRobert Mahar, Steve Webb, Ian Marschner, et al.
Seminars in Perinatology|July 8, 2023
To guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomesWilliam Odita Tarnow-Mordi, Kristy Robledo, Ian Marschner, et al.
British Journal of Anaesthesia|March 17, 2023
Importance of sequential methods in meta-analysis: implications for postoperative mortality, delirium, and stroke managementThomas Payne, Ben Moran, John Loadsman, et al.
Clinical Trials (London, England)|November 26, 2008
Parametric conditional frailty models for recurrent cardiovascular events in the lipid studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
JCO Precision Oncology|July 23, 2021
Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisPeey-Sei Kok, Won-Hee Yoon, Sally Lord, et al.
JAMA Oncology|February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysisGeorgia Ritchie, Harry Gasper, Johnathan Man, et al.
Acta Oncologica (Stockholm, Sweden)|October 15, 2019
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of biasKelli Snyders, Doah Cho, Jun Hee Hong, et al.
Pageof 4